Jushi Holdings Inc. to Report Second Quarter 2023 Financial Results on August 11, 2023

2 years ago

BOCA RATON, Fla., July 28, 2023 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),…

Press release: Online availability of Sanofi’s half-year financial report for 2023

2 years ago

Online availability of Sanofi’s half-year financial report for 2023 Paris, July 28, 2023. Sanofi announces that its half-year financial report…

Mendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue

2 years ago

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES…

Biogen to Acquire Reata Pharmaceuticals

2 years ago

SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia  Proposed acquisition represents meaningful step forward…

Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

2 years ago

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics…

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center         

2 years ago

OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading…

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

2 years ago

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 Lausanne, Switzerland, July 28, 2023 – AC Immune SA…

Augmedix to Announce Second Quarter 2023 Financial Results and Host Investor Conference Call on August 7, 2023

2 years ago

SAN FRANCISCO, July 28, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation…

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

2 years ago

Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study…

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents

2 years ago

TORONTO, July 28, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…